With Blenrep's revival, GSK dials up long-term sales goal—again—despite RSV vaccine woes
Even as GSK’s RSV vaccine launch hits a serious slowdown, the British pharma has dialed up its long-term sales guidance once again. | After re-adding Blenrep to its portfolio, GSK now expects sales to reach more than £40 billion in 2031.
GlaxoSmithKline plc (NYSE: NYSE:GSK) shares gained 5.65% after the pharmaceutical giant reported fourth quarter revenue that beat analyst estimates, despite earnings falling short of expectations.
UBS analyst Jo Walton maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £15.80. The company’s ...
GSK said it is holding steady in the face of ongoing regulatory and potential political pressures on its vaccines franchise, ...
The pharmaceutical company citied promising pipeline developments and said cancer treatments drove above-expected growth.
In a report released today, Rajan Sharma from Goldman Sachs maintained a Hold rating on GlaxoSmithKline (GSK – Research Report), with a price ...
DPA International on MSN4h
Annual core operating profit increases for British pharma GSKAnnual core operating profit increased in 2024 for British pharmaceutical company GSK compared to 2023, the company reported ...
The pharmaceutical giant targets an increase in core operating profit of between 6% and 8% in 2025, after cancer treatments ...
GSK is prioritizing development of its hepatitis B treatment bepirovirsen as the pharma ends work on another potential ...
GSK Plc announced a share buyback of £2 billion as it saw better than expected profit in the fourth quarter. The share ...
GSK Plc (NYSE:GSK) reported fourth-quarter sales of $10.40 billion (8.12 billion Sterling Pounds), up 1% year-over-year and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback